Table S1.

Safety profile

	DLX (N=287) n (%)	SSRIs (N=261) n (%)
Discontinuations due to AEs	3 (1.0)	2 (0.8)
SAEs	0 (0.0)	N/A
Subjects with ≥1 AEa	25 (8.7)	N/A
Somnolence	8 (2.8)	N/A
Nausea	6 (2.1)	N/A
Decreased appetite	3 (1.0)	N/A
Constipation	3 (1.0)	N/A
Abdominal discomfort	2 (0.7)	N/A
Malaise	2 (0.7)	N/A

Notes:

^aAEs occurred in ≥0.5% of patients. Detailed information about AEs occurring in SSRI-treated patients was not collected.

Abbreviations: AEs, adverse events; DLX, duloxetine; N, number of patients; n, number of affected patients; N/A, not available; SAEs, serious adverse events; SSRIs, selective serotonin reuptake inhibitors.